ResultsIQ

ResultsIQ › Latest results › JB Chemicals & Pharmaceuticals Limited

JB Chemicals & Pharmaceuticals Limited strategy deck summary

NSE: JBCHEPHARM · BSE: 506943

Strategy deck of 30 Jun 2025, summarised by AI from the filing.

Torrent to acquire 46.39% of JB Pharma for ₹11,917 cr and merge, creating a combined entity with FY25 pro-forma revenue of ₹15,000+ cr.

Key takeaways

  1. Acquisition Torrent to acquire 46.39% stake in JB Pharma for ₹11,917 cr at ₹1,600 per share via Share Purchase Agreement
  2. Merger Merger of Torrent with JB Pharma, Torrent surviving listed entity; JB Pharma shareholders get 51 Torrent shares per 100 held
  3. Combined entity Combined entity pro-forma FY25 revenue of ₹15,000+ cr and EBITDA of ₹4,800+ cr
  4. Ranking Combined entity 5th largest pharma company in India by secondary sales and 4th largest by prescriptions
  5. Timeline Implementation of scheme of amalgamation on an indicative timeline of 15-18 months, subject to approvals

Original filing on BSE

JB Chemicals & Pharmaceuticals Limited Q4 FY26 results

As filed: Revenue ₹904 cr (−5% year on year), EBITDA ₹201 cr (−11% year on year), PAT ₹101 cr (−16% year on year), EBITDA margin 22.2% (−157 bps).

The Q4 FY26 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q3 FY26: Revenue ₹1,065 cr (+11% year on year), EBITDA ₹296 cr (+16% year on year), PAT ₹198 cr (+22% year on year), EBITDA margin 27.8% (+130 bps). Score 57 of 100, In line with trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin rose 130 bps year on year. Profit fell 5% from last quarter. Profit rose ₹35.9 cr on a year ago, more than the ₹28.0 cr it added the year before. Share price after the results: −0.6% in 28 days (Nifty 500: −0.7%).
  • Q2 FY26: Revenue ₹1,085 cr (+8% year on year), EBITDA ₹309 cr (+14% year on year), PAT ₹208 cr (+19% year on year), EBITDA margin 28.5% (+141 bps). Score 55 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 141 bps year on year. Profit rose ₹33.0 cr on a year ago, more than the ₹24.0 cr it added the year before. Share price after the results: −0.7% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹1,094 cr (+9% year on year), EBITDA ₹301 cr (+7% year on year), PAT ₹202 cr (+14% year on year), EBITDA margin 27.5% (−47 bps). Score 33 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 47 bps year on year. Revenue rose ₹90.0 cr on a year ago, against ₹108 cr the year before. Share price after the results: −3.3% in 30 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹949 cr (+10% year on year), EBITDA ₹226 cr (+14% year on year), PAT ₹146 cr (+16% year on year), EBITDA margin 23.8% (+84 bps). Score 38 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin rose 84 bps year on year. Profit fell 10% from last quarter. Revenue rose ₹87.0 cr on a year ago, against ₹100 cr the year before. Share price after the results: +7.5% in 30 days (Nifty 500: +1.8%).
  • Q3 FY25: Revenue ₹963 cr (+14% year on year), EBITDA ₹255 cr (+14% year on year), PAT ₹162 cr (+21% year on year), EBITDA margin 26.5% (+9 bps). Score 47 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin was flat year on year. Revenue fell 4% from last quarter. Profit rose ₹28.0 cr on a year ago, against ₹28.0 cr the year before.
  • Q2 FY25: Revenue ₹1,001 cr (+13% year on year), EBITDA ₹271 cr (+12% year on year), PAT ₹175 cr (+16% year on year), EBITDA margin 27.1% (−48 bps). Score 52 of 100, In line with trend. EBITDA margin fell 48 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q1 FY25: Revenue ₹1,004 cr (+12% year on year), EBITDA ₹281 cr (+22% year on year), PAT ₹177 cr (+25% year on year), EBITDA margin 28.0% (+221 bps). Score 65 of 100, In line with trend. EBITDA margin rose 221 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

JB Chemicals & Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.